VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application for Review in the Treatment of Jet Lag Disorder
WASHINGTON , Dec. 20, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the filing of Vanda's Supplemental New Drug Application for HETLIOZ ®  (tasimelteon) for the treatment of jet lag disorder.
View HTML
Toggle Summary Vanda Announces Positive Pivotal Study Results for HETLIOZ® (tasimelteon) in Patients with Smith-Magenis Syndrome
WASHINGTON , Dec. 10, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that HETLIOZ ® (tasimelteon) improved sleep quality and increased sleep duration in patients with Smith-Magenis Syndrome (SMS) in a pivotal placebo controlled clinical study.
View HTML
Toggle Summary Vanda Announces Positive Phase II Study Results for Tradipitant in Patients with Gastroparesis
Management to host conference call on Monday, December 3 at 8:30 AM ET WASHINGTON , Dec. 3, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:VNDA) today announced that tradipitant met the primary endpoint in VLY686-2301, a Phase II clinical study in patients with idiopathic and
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at November 2018 Investor Conferences
WASHINGTON , Nov. 8, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2018 : The Stifel 2018 Healthcare Conference in New York City on Tuesday, November 13, 2018 .
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results
-- Hetlioz® net product sales grew to $29.9 million in the third quarter of 2018, a 34% increase compared to the third quarter of 2017 -- Results from clinical studies of tradipitant in gastroparesis and HETLIOZ® in Smith-Magenis Syndrome are expected by the end of 2018 WASHINGTON , Nov.
View HTML
Toggle Summary Vanda Receives FDA Letter Regarding Corporate Webpage
WASHINGTON , Nov. 1, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it received a letter from the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion on October 22, 2018 regarding the content on a single page of its corporate
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 7, 2018
Conference Call and Webcast to Follow WASHINGTON , Oct. 22, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter of 2018 on Wednesday, November 7, 2018 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at Oppenheimer and Cantor Fitzgerald Fall 2018 Investor Conferences
WASHINGTON , Sept. 26, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming 2018 investor conferences: The Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease in New York City on Thursday, September
View HTML
Toggle Summary Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book
WASHINGTON , Sept. 20, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that a HETLIOZ ®  patent, number 10,071,977 ('977 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence
View HTML
Toggle Summary HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment in Next Morning Performance
WASHINGTON , Sept. 12, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results of a HETLIOZ ® (tasimelteon) driving study to measure next day performance.  Tasimelteon did not impair measures of driving performance, whereas the active control, zopiclone,
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at September 2018 Investor Conferences
WASHINGTON , Sept. 4, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in September 2018 : The Citigroup 13 th Annual Biotech Conference in Boston on Wednesday, September 5, 2018 .
View HTML
Toggle Summary Vanda Wins Denial of Petition For Rehearing on Fanapt®
U.S. Court of Appeals Denies Petitions for Panel Rehearing and Rehearing En Banc WASHINGTON , Aug. 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit denied petitions for panel rehearing and rehearing en
View HTML
Toggle Summary Vanda Pharmaceuticals Announces the Appointment of General Counsel
WASHINGTON , Aug. 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has named Timothy Williams as Vanda's Senior Vice President, General Counsel and Secretary. "I am very pleased to welcome Tim to the Vanda executive management team," said Mihael H.
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Second Quarter 2018 Financial Results
- Total net product sales were $47.4 million in the second quarter of 2018 - Hetlioz® net product sales grew to $28.0 million in the second quarter of 2018 - Fanapt® net product sales grew to $19.3 million in the second quarter of 2018 - Vanda reiterates 2018 net product sales guidance of $180
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 1, 2018
Conference Call and Webcast to Follow WASHINGTON , July 17, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2018 on Wednesday, August 1, 2018 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at June 2018 Investor Conferences
WASHINGTON , June 1, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in June 2018 : The Jefferies 2018 Global Healthcare Conference in New York City on Tuesday, June 5, 2018 .
View HTML
Toggle Summary HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel
- HETLIOZ® demonstrates significant improvement in objective and subjective measures of Jet Lag during 5 hour and 8 hour time zone transatlantic travel from the US to the UK WASHINGTON , May 23, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from the
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON , May 7, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the Deutsche Bank 43 rd Annual Health Care Conference in Boston,
View HTML
Toggle Summary Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results
- Total net product sales were $43.6 million in the first quarter of 2018 - Vanda reiterates 2018 net product sales guidance of $180 million to $200 million WASHINGTON , May 2, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ) today announced financial and operational results
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018
Conference Call and Webcast to Follow WASHINGTON , April 18, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2018 on Wednesday, May 2, 2018 , after the market closes.
View HTML
Toggle Summary Vanda Wins Appeal Case on Fanapt®
U.S. Court of Appeals Affirms District Court's Decision WASHINGTON , April 13, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware's decision that
View HTML
Toggle Summary Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis
WASHINGTON , April 9, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced participation at the 2018 Georg Rajka International Symposium of Atopic Dermatitis (ISAD 2018) in Utrecht, Netherlands in the scientific poster forum on Thursday, April 12, 2018 .
View HTML
Toggle Summary Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock
WASHINGTON , March 15, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the sale of 5,500,000 shares of its common stock in an underwritten public offering at a price to the public of $17.00 per share. The gross offering proceeds to Vanda from the sale of the
View HTML
Toggle Summary Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
WASHINGTON , March 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences
WASHINGTON , March 6, 2018 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in March 2018 . The Cowen and Company 38 th Annual Healthcare Conference in Boston on Monday, March 12, 2018 .
View HTML
Copyright © 2005-2020 Vanda Pharmaceuticals Inc. |